LU90311I2 - Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci - Google Patents

Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci

Info

Publication number
LU90311I2
LU90311I2 LU90311C LU90311C LU90311I2 LU 90311 I2 LU90311 I2 LU 90311I2 LU 90311 C LU90311 C LU 90311C LU 90311 C LU90311 C LU 90311C LU 90311 I2 LU90311 I2 LU 90311I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
precursors
prodrugs
alatrofloxacin
trovafloxacin
Prior art date
Application number
LU90311C
Other languages
English (en)
Inventor
Katherine Elizabeth Brighty
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of LU90311I2 publication Critical patent/LU90311I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
LU90311C 1989-08-16 1998-11-04 Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci LU90311I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/003489 WO1991002526A1 (fr) 1989-08-16 1989-08-16 Acides azabicyclo quinolone carboxyliques

Publications (1)

Publication Number Publication Date
LU90311I2 true LU90311I2 (fr) 1999-01-25

Family

ID=22215165

Family Applications (2)

Application Number Title Priority Date Filing Date
LU90311C LU90311I2 (fr) 1989-08-16 1998-11-04 Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci
LU90310C LU90310I2 (fr) 1989-08-16 1998-11-04 Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU90310C LU90310I2 (fr) 1989-08-16 1998-11-04 Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti

Country Status (29)

Country Link
EP (1) EP0413455B1 (fr)
JP (2) JPH072734B2 (fr)
KR (1) KR930004844B1 (fr)
CN (1) CN1025192C (fr)
AT (1) ATE124040T1 (fr)
AU (1) AU623801B2 (fr)
BA (1) BA98299A (fr)
CA (2) CA2127561C (fr)
CY (2) CY1969A (fr)
CZ (1) CZ281127B6 (fr)
DD (1) DD298399A5 (fr)
DE (3) DE19875050I2 (fr)
DK (1) DK0413455T3 (fr)
EG (1) EG19251A (fr)
ES (1) ES2074131T4 (fr)
FI (2) FI108228B (fr)
GR (1) GR3017072T3 (fr)
HU (2) HU219403B (fr)
IE (1) IE66202B1 (fr)
IL (1) IL95331A (fr)
LU (2) LU90311I2 (fr)
NL (2) NL980032I2 (fr)
NO (1) NO300214B1 (fr)
NZ (1) NZ234920A (fr)
PL (1) PL166381B1 (fr)
PT (1) PT94998B (fr)
RU (1) RU2049777C1 (fr)
WO (1) WO1991002526A1 (fr)
ZA (1) ZA906450B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
FR2675144B1 (fr) * 1991-04-10 1995-06-16 Bouchara Sa Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant.
JPH0678335B2 (ja) * 1991-06-19 1994-10-05 ファイザー・インコーポレーテッド アザスピロキノロン化合物、その製法および抗菌組成物
US5256791A (en) * 1992-03-02 1993-10-26 Pfizer Inc. Preparation of intermediates in the synthesis of quinoline antibiotics
EG20543A (en) * 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
US5527910A (en) * 1992-12-30 1996-06-18 Cheil Foods & Chemicals, Inc. Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria
US5591766A (en) * 1993-12-03 1997-01-07 Cheil Foods & Chemicals, Inc. Solid oral formulations of pyridone carboxylic acids
US5990106A (en) * 1994-02-04 1999-11-23 Dainippon Pharmaceutical Co., Ltd. Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof
WO1996023782A1 (fr) * 1995-02-02 1996-08-08 Daiichi Pharmaceutical Co., Ltd. Composes heterocycliques
JPH08213881A (ja) * 1995-02-02 1996-08-20 Fujitsu Ltd 周波数制御回路
WO1996024593A1 (fr) * 1995-02-07 1996-08-15 Daiichi Pharmaceutical Co., Ltd. Derives spiro heterocycliques
DK0789697T3 (da) * 1995-06-06 1998-10-19 Pfizer Krystalform af vandfrit 7-([1alfa, 5alfa, 6alfa,]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-fluor-1-(2,4-difluorphenyl)-1,4-d
DE69622715T2 (de) * 1995-06-15 2002-11-14 Pfizer Inc., New York Verfahren zur herstellung von derivaten der ein peptid enthaltenden azabizylo-naphtyridin-carbonsäure
ATE229950T1 (de) * 1996-02-09 2003-01-15 Toyama Chemical Co Ltd Chinolin carbonsaure-derivate und ihre salze
AP788A (en) * 1996-08-26 1999-12-03 Pfizer Novel crystal form of anhydrous 7-(1a, 5a, 6a)-6-Amino-3-Azabicyclo(3.1.0) hex-3-YI)-6-Fluoro-1-(2,4- Difluorophenyl)-1,4-Dihydro-4-Oxo-1, 8-Naphthyridine-3-Carboxylic Acid, Methanesulfonic acid salt.
TW519542B (en) * 1996-09-27 2003-02-01 Daiichi Seiyaku Co Bicyclic amine derivative
US6384050B1 (en) * 1996-10-25 2002-05-07 Daiichi Pharmaceutical Co., Ltd. Tricyclic amine derivatives
MA24500A1 (fr) 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
US20020032216A1 (en) 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
DE19733439A1 (de) * 1997-08-02 1999-02-04 Bayer Ag Neue 6-endo-Amino-3-azabicyclo(3.1.0)hexande, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung von Chinolon- und Naphthyridincarbonsäure-Derviaten mit verbesserten Eigenschaften
SK286420B6 (sk) 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US7019142B2 (en) 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
PA8464701A1 (es) * 1998-01-16 2000-09-29 Pfizer Prod Inc Procedimiento e intermedios para preparar naftiridonas
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3192700A (en) 1999-03-17 2000-10-04 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
ATE304539T1 (de) 2000-12-14 2005-09-15 Procter & Gamble Antimikrobielle chinolone
HUP0303457A3 (en) 2000-12-14 2008-05-28 Procter & Gamble Antimicrobial 2-pyridones, compositions containing them and their use
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
EA009059B1 (ru) 2003-04-10 2007-10-26 Рэнбакси Лабораториз Лимитед Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
JP2006522787A (ja) 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2005026147A1 (fr) 2003-09-10 2005-03-24 Kyorin Pharmaceutical Co., Ltd. Derive d'acide quinolonecarboxylique 7-(4-substitue 3-cyclopropylaminomethyl-1-pyrrolidinyle)
EP1670759A1 (fr) * 2003-09-18 2006-06-21 Ranbaxy Laboratories Limited Procede de preparation de (1$g(a), 5$g(a), 6$g(a))-6-aminomethyl-3-benzyl-3-azabicyclo 3.1.0|hexane
TWI391378B (zh) * 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
MX2008012488A (es) 2006-03-28 2008-10-10 Procter & Gamble Un proceso de acoplamiento para preparar intermedios de quinolona.
EP2001862B1 (fr) 2006-03-28 2011-04-27 Warner Chilcott Company, LLC Malates et formes polymorphes de l'acide (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinoleine-carboxylique
US7902227B2 (en) * 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
WO2020073031A1 (fr) * 2018-10-05 2020-04-09 New York University Hétérocycles bicycliques fusionnés en tant qu'agents thérapeutiques
CN112442084B (zh) * 2020-12-03 2022-09-09 国药集团致君(深圳)制药有限公司 一种抗菌药中间体的制备方法
CN113307768B (zh) * 2021-04-29 2023-12-12 中国农业科学院兰州畜牧与兽药研究所 喹诺酮类衍生物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676400B2 (ja) * 1987-08-25 1994-09-28 大日本製薬株式会社 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
US4973091A (en) * 1989-09-20 1990-11-27 Truth Incorporated Sliding patio door dual point latch and lock

Also Published As

Publication number Publication date
EP0413455A2 (fr) 1991-02-20
FI103879B1 (fi) 1999-10-15
PT94998A (pt) 1991-04-18
GR3017072T3 (en) 1995-11-30
NO300214B1 (no) 1997-04-28
FI964520A0 (fi) 1996-11-11
CN1025192C (zh) 1994-06-29
CA2127561A1 (fr) 1991-02-17
AU623801B2 (en) 1992-05-21
NO920599D0 (no) 1992-02-14
NZ234920A (en) 1992-06-25
NL980032I2 (nl) 1999-05-03
BA98299A (bs) 2001-09-14
DE19875052I2 (de) 2009-05-28
ZA906450B (en) 1992-03-25
KR910004572A (ko) 1991-03-28
CY1969A (en) 1997-09-05
JPH07149758A (ja) 1995-06-13
HU211681A9 (en) 1995-12-28
EP0413455A3 (en) 1991-10-09
PT94998B (pt) 1997-05-28
AU6104290A (en) 1991-02-21
CZ402790A3 (en) 1996-04-17
FI108228B (fi) 2001-12-14
DK0413455T3 (da) 1995-08-14
NL980032I1 (nl) 1999-02-01
FI920632A0 (fi) 1992-02-14
ES2074131T3 (es) 1995-09-01
HU219403B (hu) 2001-04-28
JPH072734B2 (ja) 1995-01-18
IL95331A0 (en) 1991-06-30
CZ281127B6 (cs) 1996-06-12
KR930004844B1 (ko) 1993-06-09
PL166381B1 (pl) 1995-05-31
CN1049501A (zh) 1991-02-27
DE19875050I2 (de) 2009-05-28
ES2074131T4 (es) 1996-05-01
DD298399A5 (de) 1992-02-20
NL980033I1 (nl) 1999-02-01
DE69020262T2 (de) 1995-10-26
HK1000207A1 (en) 1998-02-06
IE66202B1 (en) 1995-12-13
JPH0386875A (ja) 1991-04-11
IE902950A1 (en) 1991-02-27
IL95331A (en) 1995-07-31
WO1991002526A1 (fr) 1991-03-07
FI964520L (fi) 1996-11-11
CA2023217C (fr) 1996-12-10
NL980033I2 (nl) 1999-05-03
EP0413455B1 (fr) 1995-06-21
FI103879B (fi) 1999-10-15
CA2127561C (fr) 1998-07-28
JPH0819099B2 (ja) 1996-02-28
NO920599L (no) 1992-04-14
PL286484A1 (en) 1991-05-20
LU90310I2 (fr) 1999-01-25
CY99010I2 (en) 2010-07-28
EG19251A (en) 1994-09-29
RU2049777C1 (ru) 1995-12-10
ATE124040T1 (de) 1995-07-15
CA2023217A1 (fr) 1991-02-17
DE69020262D1 (de) 1995-07-27

Similar Documents

Publication Publication Date Title
LU90311I2 (fr) Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci
RU2000111540A (ru) Агонисты аполипопротеина а-1 и их применение для лечения заболеваний, связанных с дислипидемией
KR950701937A (ko) 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives)
AR012588A1 (es) UN INHIBIDOR DE SERINA PROTEASA, UNA COMPOSICIoN FARMACEUTICA QUE LO COMPRENDE Y UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICIoN FARMACEUTICA
KR970042553A (ko) 캠프토테신 유도체
EE02950B1 (et) Metüleenbisfosfoonhappe esteramiidderivaadid, meetod nende valmistamiseks ja farmatseutiline kompositsioon
HU9301520D0 (en) Methods for producing cyclopeptides promoting absorption of peptides and albumins through mucous membrane as well as pharmaceutical preparations containing said compounds as auxiliary agents
CA2215827A1 (fr) Composes a base d'o-malonyltyrosyle, peptides contenant des composes a base d'o-malonyltyrosyle et leurs utilisations
KR900009692A (ko) 레트로바이러스 프로테아제 억제제
JP2002522508A5 (fr)
CA2102606A1 (fr) Compositions pour le traitement du syndrome de fatigue chronique
JPH09124692A5 (fr)
EP0346068A3 (fr) Antagonistes de D-Cys6-vasopressine
JPH11514858A (ja) 骨刺激因子
NZ822560A (en) Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same
NZ822560B2 (en) Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same
US6218364B1 (en) Fluorinated neurokinin A antagonists
HUT59919A (en) Process for producing azabicyclo-quinolon and naphtiridone derivatives and pharmaceutical compositions containing them
RU2008129731A (ru) Новые пептиды-т-хелперные антигенные детерминанты (thd)
ES2005778A6 (es) Procedimiento para la obtencion de derivados de diisobutilxantina.
RU98117609A (ru) Пептидные производные
RU97112094A (ru) Ингибиторы фибронектиновой адгезии